GLP-1 Market
LLY $1145.46 ▼ -1.0% NVO $37.49 ▼ -1.1% PFE $28.29 ▼ -0.8% VKTX $31.28 ▼ -4.0% KLRA $10.77 ▼ -5.7% GPCR $30.27 ▼ -3.2% RHHBY $51.91 ▼ -0.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

glepaglutide

Company
Zealand Pharma
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 1, 2026

Find a Clinical Trial Near Me

See recruiting studies for glepaglutide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07197944

    Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

    Not yet reported Zealand Pharma 90 participants Est. completion 2032-02-28 33 sites Stand-alone
    Other conditions: Short Bowel Syndrome
    View official trial listing →
  • Completed NCT NCT00868660

    Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose

    Not yet reported Zealand Pharma 66 participants Est. completion 2010-02 1 site Stand-alone
    Other conditions: Inflammatory Bowel Disease
    View official trial listing →
  • Completed NCT NCT02690025

    A Phase 2 Trial Testing ZP1848 in Patients With SBS

    Not yet reported Zealand Pharma 18 participants Est. completion 2017-05 1 site Stand-alone
    Other conditions: Short Bowel Syndrome
    View official trial listing →
  • Completed NCT NCT03279302

    Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects

    Not yet reported Zealand Pharma 75 participants Est. completion 2017-12-18 1 site Stand-alone
    Other conditions: Healthy Subjects
    View official trial listing →
  • Completed NCT NCT03690206

    Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)

    Not yet reported Zealand Pharma 106 participants Est. completion 2022-07-26 29 sites Stand-alone
    Other conditions: Short Bowel Syndrome
    View official trial listing →
  • Completed NCT NCT03905707

    Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

    Not yet reported Zealand Pharma 150 participants Est. completion 2026-04-30 27 sites Stand-alone
    Other conditions: Short Bowel Syndrome
    View official trial listing →
  • Completed NCT NCT04178447

    Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function

    Not yet reported Zealand Pharma 16 participants Est. completion 2020-07-14 3 sites Stand-alone
    Other conditions: Renal Impairment
    View official trial listing →
  • Completed NCT NCT04318743

    A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.

    Not yet reported Zealand Pharma 85 participants Est. completion 2021-06-10 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT04881825

    Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

    Not yet reported Zealand Pharma 84 participants Est. completion 2026-04-30 19 sites Stand-alone
    Other conditions: Short Bowel Syndrome
    View official trial listing →
  • Completed NCT NCT04991311

    The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome

    Not yet reported Zealand Pharma 12 participants Est. completion 2023-09-05 1 site Stand-alone
    Other conditions: Short Bowel Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT07228403

    Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome

    Not yet reported Zealand Pharma 28 participants Est. completion 2028-12-31 16 sites Stand-alone
    Other conditions: Short Bowel Syndrome (SBS)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: glepaglutide, ZP1848

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.